Immuno-Oncology Drugs Market Size and Share, By Drug and Cancer Type - Global Industry Insights, Trends, Outlook, and Opportunity Analysis 2017-2025
Natural immunity system holds superior potential to specifically target and destruct tumors while avoiding harm to the normal healthy tissue along with long term memory to prevent cancer recurrence. Immuno-oncology research has supported the fact that immunity system can effectively identify tumors and can stop or control long term growth of the same through immunosurveillance. However, cancer progression leads to suppression of immunity systems natural functioning wherein immune-oncology therapies play an important role. Advent of innovative immune-oncology therapies such as immune-checkpoint inhibitors, therapeutic cancer vaccines, and CAR-T therapies has spurred leading organizations to actively invest into research and development. However, high costs associated with therapy is restraining growth of the immuno-oncology drugs market.
Market Dynamics
Global Immuno-oncology drugs market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immuno-oncology drugs in the pipeline such as CAR-T cell therapy offered by Juno Therapeutics, Inc. and Kite Pharma. Immuno-oncology drugs has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost growth of the immuno-oncology drugs market.
Key features of the study:
This report provides in-depth analysis of global immuno-oncology drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
Key companies covered as a part of this study include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, By Technology up-gradation, market expansion, and marketing tactics
The global immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the global immuno-oncology drugs market
Detailed Segmentation:
Global Immuno-Oncology Drugs Market, By Drug Type:
Immune Checkpoint Inhibitors
CTL-4 Checkpoint Inhibitor
Iplimumab
PD-1 & PD-L1 Checkpoint Inhibitor
Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
Monoclonal Antibodies
Naked Monoclonal Antibodies
Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Ibrotumomab Tiuxetan (Zevalin)
Chemo labeled Antibodies
Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)
Bispecific Monoclonal Antibodies
Blinatumomab (Blincyto)
Cytokine Based Immunotherapy
Intron A
Proleukin
Cancer Vaccines
Preventive Vaccines
Gardasil
Cervarix
Treatment Vaccines
Sipuleucel-T (Provenge)
CAR-T Cell Therapy
Kymriah
Yescarta
Global Immuno-Oncology Drugs Market, By Cancer Type:
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers
Global Immuno-Oncology Drugs Market, By Geography:
North America
By Drug Type
Immune Checkpoint Inhibitors
CTL-4 Checkpoint Inhibitor
Iplimumab
PD-1 & PD-L1 Checkpoint Inhibitor
Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
Monoclonal Antibodies
Naked Monoclonal Antibodies
Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Ibrotumomab Tiuxetan (Zevalin)
Chemo labeled Antibodies
Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)
Bispecific Monoclonal Antibodies
Blinatumomab (Blincyto)
Cytokine Based Immunotherapy
Intron A
Proleukin
Cancer Vaccines
Preventive Vaccines
Gardasil
Cervarix
Treatment Vaccines
Sipuleucel-T (Provenge)
CAR-T Cell Therapy
Kymriah
Yescarta
By Cancer Type:
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers
By Country:
U.S.
Canada
Europe
By Drug Type
Immune Checkpoint Inhibitors
CTL-4 Checkpoint Inhibitor
Iplimumab
PD-1 & PD-L1 Checkpoint Inhibitor
Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
Monoclonal Antibodies
Naked Monoclonal Antibodies
Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Ibrotumomab Tiuxetan (Zevalin)
Chemo labeled Antibodies
Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)
Bispecific Monoclonal Antibodies
Blinatumomab (Blincyto)
Cytokine Based Immunotherapy
Intron A
Proleukin
Cancer Vaccines
Preventive Vaccines
Gardasil
Cervarix
Treatment Vaccines
Sipuleucel-T (Provenge)
CAR-T Cell Therapy
Kymriah
Yescarta
By Cancer Type:
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers
By Country:
U.K.
Germany
Italy
France
Russia
Spain
Rest of Europe
Asia Pacific
By Drug Type
Immune Checkpoint Inhibitors
CTL-4 Checkpoint Inhibitor
Iplimumab
PD-1 & PD-L1 Checkpoint Inhibitor
Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
Monoclonal Antibodies
Naked Monoclonal Antibodies
Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Ibrotumomab Tiuxetan (Zevalin)
Chemo labeled Antibodies
Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)
Bispecific Monoclonal Antibodies
Blinatumomab (Blincyto)
Cytokine Based Immunotherapy
Intron A
Proleukin
Cancer Vaccines
Preventive Vaccines
Gardasil
Cervarix
Treatment Vaccines
Sipuleucel-T (Provenge)
CAR-T Cell Therapy
Kymriah
Yescarta
By Cancer Type:
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of APAC
Latin America
By Drug Type
Immune Checkpoint Inhibitors
CTL-4 Checkpoint Inhibitor
Iplimumab
PD-1 & PD-L1 Checkpoint Inhibitor
Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
Monoclonal Antibodies
Naked Monoclonal Antibodies
Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Ibrotumomab Tiuxetan (Zevalin)
Chemo labeled Antibodies
Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)
Bispecific Monoclonal Antibodies
Blinatumomab (Blincyto)
Cytokine Based Immunotherapy
Intron A
Proleukin
Cancer Vaccines
Preventive Vaccines
Gardasil
Cervarix
Treatment Vaccines
Sipuleucel-T (Provenge)
CAR-T Cell Therapy
Kymriah
Yescarta
By Cancer Type:
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers
By Country:
Brazil
Mexico
Argentina
Rest of LATAM
Middle East
By Drug Type
Immune Checkpoint Inhibitors
CTL-4 Checkpoint Inhibitor
Iplimumab
PD-1 & PD-L1 Checkpoint Inhibitor
Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
Monoclonal Antibodies
Naked Monoclonal Antibodies
Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Ibrotumomab Tiuxetan (Zevalin)
Chemo labeled Antibodies
Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)
Bispecific Monoclonal Antibodies
Blinatumomab (Blincyto)
Cytokine Based Immunotherapy
Intron A
Proleukin
Cancer Vaccines
Preventive Vaccines
Gardasil
Cervarix
Treatment Vaccines
Sipuleucel-T (Provenge)
CAR-T Cell Therapy
Kymriah
Yescarta
By Cancer Type:
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type
Immune Checkpoint Inhibitors
CTL-4 Checkpoint Inhibitor
Iplimumab
PD-1 & PD-L1 Checkpoint Inhibitor
Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
Monoclonal Antibodies
Naked Monoclonal Antibodies
Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Ibrotumomab Tiuxetan (Zevalin)
Chemo labeled Antibodies
Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)
Bispecific Monoclonal Antibodies
Blinatumomab (Blincyto)
Cytokine Based Immunotherapy
Intron A
Proleukin
Cancer Vaccines
Preventive Vaccines
Gardasil
Cervarix
Treatment Vaccines
Sipuleucel-T (Provenge)
CAR-T Cell Therapy
Kymriah
Yescarta
By Cancer Type:
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers
By Country:
North Africa
Central Africa
South Africa
Company Profiles
Amgen, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
“*” marked represents similar segmentation in other categories in the respective section.
- 1. Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Cancer Type
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Immuno-Oncology Overview
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- PEST Analysis
- PORTER’s Five Forces Analysis
- Mergers & Acquisitions
- Epidemiology
- Research Update & Pipeline Analysis (For each drug category)
- Major FDA Approvals & Product Launch Scenario (For each drug category)
- Regulatory Scenario
- Reimbursement Scenario
- Immunotherapy Combination Therapies In Development
- Adoptive Cell Transfer Therapies
- 4. Global Immuno-Oncology Drugs Market, By Drug Type, 2017–2025 (US$ Mn)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2016–2025
- Segment Trends
- Immune Checkpoint Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- CTL-4 Checkpoint Inhibitor
- Iplimumab
- PD-1 & PD-L1 Checkpoint Inhibitor
- Nivolumab (Opdivo)
- Atezolimumab (Tecentriq)
- Pembrolizumab (Keytruda)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Naked Monoclonal Antibodies
- Rituximab (Rituxan)
- Trastazumab (Herceptin)
- Bevacizumab (Avastin)
- Others
- Conjugated Monoclonal Antibodies
- Radiolabeled Antibodies
- 1. Ibrotumomab Tiuxetan (Zevalin)
- Chemo labeled Antibodies
- 1. Brentixumab Vedotin (Adcetris)
- 2. Trastuzumab Emtansine (Kadcyla)
- Bispecific Monoclonal Antibodies
- 1. Blinatumomab (Blincyto)
- Cytokine Based Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Intron A
- Proleukin
- Cancer Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Preventive Vaccines
- Gardasil
- Cervarix
- Treatment Vaccines
- Sipuleucel-T (Provenge)
- CAR-T Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Kymriah
- Yescarta
- 5. Global Immuno-Oncology Drugs Market, By Cancer Type, 2017–2025 (US$ Mn)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2016–2025
- Segment Trends
- Non-Small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Acute Myeloid Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Gastric Cancers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Glioblastoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- Head & Neck Cancers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
- 6. Global Immuno-Oncology Drugs Market, By Regions, 2017–2025 (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2016–2025
- North America
- Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of APAC
- Latin America
- Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East
- Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
- Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
- North Africa
- Central Africa
- South Africa
- 7. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Amgen, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene Corporation
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- EMD Serono, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Prometheus Therapeutics & Diagnostics
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aduro BioTech
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Galena Biopharma
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bavarian Nordic
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celldex Therapeutics
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ImmunoCellular Therapeutics
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Incyte
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 8. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 25 market data tables and 38 figures on "Immuno-Oncology Drugs Market - Global forecast to 2025”
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook